Canada's health regulator approved Novo Nordisk's weight loss drug Wegovy on November 27, 2024, to reduce the risk of nonfatal heart attack or myocardial infarction in some adults. This approval expands the drug's indications beyond its primary use for obesity.
The decision is based on findings from the randomized, placebo-controlled SELECT trial, demonstrating Wegovy's cardiovascular benefits. This label expansion provides a stronger clinical profile for the drug, appealing to a broader patient population with co-morbidities.
This approval reinforces Wegovy's value proposition by highlighting its ability to address serious cardiovascular events in addition to weight management. It strengthens Novo Nordisk's position in the competitive metabolic health market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.